Oncotarget: Tumor Suppressor Gene Alterations in Pituitary Neuroendocrine Tumors
Channel: Oncotarget
Date: 2021-04-15

Oncotarget published this trending paper on July 14, 2020, entitled, “Genetic analysis of the cooperative tumorigenic effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in mice,” by researchers from the Rutgers Cancer Institute of New Jersey; Department of Pediatrics Robert Wood Johnson Medical School, Rutgers; Department of Molecular Biology, Princeton University; Department of Medicine, Veterans Administration Hospital; Department of Medicine, Yale University School of Medicine; Department of Pathology, Memorial Sloan-Kettering Cancer Center.

Abstract:
“Genetic alterations of tumor suppressor genes (TSGs) are frequently observed to have cumulative or cooperative tumorigenic effects. We examined whether the TSGs Rb1, Trp53, Pten and Men1 have cooperative effects in suppressing neuroendocrine tumors (NETs) in mice. We generated pairwise homozygous deletions of these four genes in insulin II gene expressing cells using the Cre-LoxP system. By monitoring growth and examining the histopathology of the pituitary (Pit) and pancreas (Pan) in these mice, we demonstrated that pRB had the strongest cooperative function with PTEN in suppressing PitNETs and had strong cooperative function with Menin and TRP53, respectively, in suppressing PitNETs and PanNETs. TRP53 had weak cooperative function with PTEN in suppressing pituitary lesions. We also found that deletion of Pten singly led to prolactinomas in female mice, and deletion of Rb1 alone led to islet hyperplasia in pancreas. Collectively, our data indicated that pRB and PTEN pathways play significant roles in suppressing PitNETs, while the Menin-mediated pathway plays a significant role in suppressing PanNETs. Understanding the molecular mechanisms of these genes and pathways on NETs will help us understand the molecular mechanisms of neuroendocrine tumorigenesis and develop effective preclinical murine models for NET therapeutics to improve clinical outcomes in humans.”

To date, this research paper has generated an Altmetric Attention score of 63. Altmetric Attention scores, located at the top-left of trending Oncotarget papers, provide an at-a-glance indication of the volume and type of online attention the research has received. 
Top Oncotarget publications rated by Altmetric score: https://www.oncotarget.com/news/altmetric/

Sign up for free Altmetric alerts about this article: 
DOI: https://doi.org/10.18632/oncotarget.27660
Full text: https://www.oncotarget.com/article/27660/text/

Correspondence to: Eugenia Y. Xu - exu@princeton.edu; Daniel A. Notterman - dan1@princeton.edu

About Oncotarget:

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
YouTube - https://www.youtube.com/c/OncotargetYouTube/
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957